A short briefing on why “quantum plus classical” not the fully fault-tolerant machine will deliver the first real-world advantage. Let’s see the current reality behind the headlines.

For a decade, the quantum-computing narrative has been anchored to a single, distant milestone: the large-scale, fault-tolerant quantum computer capable of running error-free calculations across millions of qubits. That machine is coming, IBM now targets its first fault-tolerant system, Starling, for 2029 but it is not what will deliver value first (IBM, 2026a).

The more consequential story of 2026 is quieter and more pragmatic. In a July 2026 editorial, Nature Biotechnology stated the point plainly: “Hybrid quantum-classical computers will achieve quantum advantage in biotechnology, bridging the time until a full quantum computer becomes available” (Nature Biotechnology, 2026).

Quantum advantage, the moment at which a quantum computer provides a meaningful practical benefit over the best available classical methods is widely expected to emerge through hybrid quantum-classical systems. Rather than relying on standalone quantum processors, many researchers and technology companies are developing architectures that combine quantum hardware with classical high-performance computing (HPC), using each platform for the tasks it performs best. This hybrid approach is currently viewed as one of the most promising paths toward practical quantum applications.

Hybrid Quantum-Classical Computing: Where Are We Today?

Why “hybrid” is the architecture, not a compromise?

Today’s quantum processors are Noisy Intermediate-Scale Quantum (NISQ) devices: they hold dozens to a few hundred qubits, are not error-corrected, and introduce errors as vibration, temperature drift, or stray electromagnetic fields cause qubits to lose coherence (Nature Biotechnology, 2026).

Hybrid systems work around this constraint rather than waiting for it to be solved. Classical and quantum computers are coupled in tight, iterative loops: the quantum-mechanical core of a problem runs on the quantum hardware, while the classical machine handles optimisation, data processing, and quantum error mitigation, techniques that statistically reduce the impact of noise without the massive qubit overhead of full error correction (Nature Biotechnology, 2026).

IBM argues that practical quantum advantage is likely to emerge from hybrid quantum-classical computing rather than from standalone quantum processors. In its public roadmap and technical guidance, the company describes quantum advantage as the point at which a quantum system, working alongside classical computing resources, delivers better results than classical methods alone. IBM also identifies error mitigation as a critical near-term capability, enabling useful quantum computations on noisy hardware while the industry progresses toward fully fault-tolerant quantum computers.

IBM describes its long-term hybrid computing strategy as quantum-centric supercomputing (QCSC), in which CPUs, GPUs, and quantum processing units (QPUs) operate within a unified computing environment. In 2026, IBM published a quantum-centric supercomputing reference architecture that positions QPUs as specialised accelerators integrated into existing high-performance computing (HPC) systems. Under this model, quantum processors are expected to augment classical computing workflows in much the same way that GPUs accelerate selected computational tasks within modern CPU-based architectures.

The proof points are already on the table

What separates 2026 from earlier “someday” claims is a run of concrete, peer-reviewed and independently reported results – all produced on hybrid platforms.

In research published in 2026, Cleveland Clinic and IBM demonstrated a hybrid Sample-based Quantum Diagonalization (SQD) workflow using IBM’s 156-qubit Heron r2 processor to study the Trp-cage miniprotein, a molecular system containing approximately 300 atoms and 919 orbitals. The quantum-classical workflow scaled simulations to 33 active orbitals and produced energy estimates that IBM reported as comparable to established classical quantum-chemistry methods such as Coupled Cluster Singles and Doubles (CCSD). IBM described the study as one of the largest molecular simulations performed within a quantum-centric supercomputing framework.

IBM and RIKEN demonstrated a hybrid quantum-classical workflow for simulating biologically important iron–sulfur clusters, combining IBM Heron quantum processors with Japan’s Fugaku supercomputer. The work, published in Science Advances, illustrates how quantum hardware can be integrated into large-scale classical HPC workflows for chemically relevant simulations. (IBM, 2025; IBM Newsroom, 2026).

Researchers have also explored genomics applications on IBM quantum hardware, including studies involving the hepatitis D virus genome. Separately, the Quantum for Bio (Q4Bio) initiative reported hybrid simulations of protein complexes exceeding 12,000 atoms, which participants described as among the largest quantum-assisted simulations of biologically relevant molecular systems.

In optimization, Kipu Quantum reported runtime advantages on selected higher-order binary optimization problems, while Q-CTRL demonstrated that advanced error-suppression techniques could increase the size of optimization problems solvable on IBM quantum systems relative to baseline approaches. These results highlight the role of quantum processors as accelerators within broader optimization workflows.

Taken together, these examples illustrate the current trajectory of practical quantum computing. Rather than replacing classical supercomputers, quantum processors are increasingly being deployed as specialised accelerators within hybrid workflows that combine quantum hardware with high-performance classical computing. The most significant advances reported to date have emerged from these quantum-classical systems, reinforcing the view that early quantum advantage is likely to arise through augmentation of existing computational pipelines rather than through standalone quantum machines.

How the drug-discovery pipeline actually uses this?

Drug discovery is widely regarded as one of the most promising long-term applications of quantum computing. The field faces two major computational challenges: an enormous chemical search space, often estimated at around 10⁶⁰ drug-like molecules and the difficulty of accurately modelling molecular behaviour using quantum mechanics. Hybrid quantum-classical approaches aim to address these challenges.

The Variational Quantum Eigensolver (VQE), a hybrid quantum-classical algorithm, uses quantum circuits to prepare trial molecular states while a classical optimiser iteratively searches for lower-energy solutions. Researchers have also explored the Quantum Approximate Optimisation Algorithm (QAOA) for combinatorial optimisation problems relevant to drug discovery and clinical research. In addition, quantum machine-learning approaches, including quantum kernel and generative methods, are being investigated for molecular-property prediction and de novo molecule design.

Industry participants such as IBM argue that near-term value is likely to come from incremental improvements to high-value scientific workflows rather than from fully replacing classical computing. Major pharmaceutical companies are increasingly exploring quantum-computing initiatives, and IBM has announced collaborations with organisations including Moderna and Algorithmiq.

A caveat worth noting is that many industry analysts believe practical, independently verified quantum advantage in drug-discovery applications is still several years away. While projections vary, some forecasts place the first meaningful demonstrations in the 2027–2028 timeframe. To date, most reported successes have been small-scale hybrid quantum-classical studies and proof-of-concept demonstrations rather than examples of quantum systems delivering clear commercial advantages in pharmaceutical research.

See it in action

One of the most prominent recent demonstrations of hybrid quantum-classical computing was presented by Q-CTRL at IBM Think 2026. Using Q-CTRL’s error-suppression software on IBM quantum hardware, the team reported a materials-science calculation involving large-scale quantum operations that significantly outperformed a selected classical benchmark. While the precise performance gains depend on the benchmark methodology, the demonstration illustrated the central theme of near-term quantum computing: practical results emerging from hybrid workflows that combine quantum processors with classical computing resources, rather than from standalone quantum machines.

Q-CTRL at IBM Think 2026 I Practical quantum advantage for materials discovery

The corporate reckoning: security cannot wait

Hybrid systems also force a security conversation that boards should be having now. The same trajectory that brings useful quantum computing brings the ability to break today’s encryption. Resource estimates for cracking RSA-2048 have fallen dramatically, from roughly 20 million physical qubits to potentially fewer than 100,000 under new algorithms and architectures (Nature Biotechnology, 2026).

The threat is not purely future-tense. A “harvest now, decrypt later” strategy means encrypted data intercepted today can be stored and decrypted once hardware matures. Genomic and health data are uniquely exposed because they do not expire. Post-quantum cryptographic standards have been available since 2024 (Nature Biotechnology, 2026), and IBM’s roadmap urges enterprises requiring strong data protection to begin cryptographic inventory, risk assessment, and migration immediately (IBM, 2026a).

What the roadmap currently suggests

For planning purposes, the most credible near-term outlook is based on a combination of published hardware roadmaps and industry forecasts.

2026. IBM’s roadmap targets early demonstrations of quantum utility through hybrid quantum-classical computing. The company’s Nighthawk processor is expected to support deeper quantum circuits and modular execution, with quantum processors operating alongside high-performance computing (HPC) systems rather than independently.

2027–2028. Many analysts view this period as a plausible window for the first independently verified examples of quantum advantage in areas such as chemistry and drug discovery, although timelines remain uncertain and no consensus date exists.

2029–2030. IBM’s roadmap targets deployment of its fault-tolerant Starling system, designed to execute large-scale error-corrected quantum computations that exceed the capabilities of current noisy quantum hardware.

IBM CEO Arvind Krishna has argued that practical quantum advantage could begin to emerge during the second half of the decade. Consistent with IBM’s broader quantum-centric supercomputing strategy, these advances are expected to rely heavily on hybrid architectures in which classical systems handle orchestration, data preparation, and supporting computational tasks while quantum processors accelerate selected workloads.

The Strategic Takeaway

Quantum computing is unlikely to transform biotechnology, finance, or materials science through a single breakthrough. Instead, current evidence suggests that progress is emerging through hybrid quantum-classical systems that combine the strengths of quantum processors with the scale and reliability of classical computing. While large-scale fault-tolerant quantum computers remain under development, these hybrid approaches are already enabling experimental advances in chemistry, optimisation, and scientific computing.

The emerging opportunity is therefore less about replacing classical computing than about integrating quantum capabilities into existing computational ecosystems. Organisations that develop experience with hybrid quantum-classical workflows today may be better positioned to exploit future advances as quantum technologies mature.

For decision-makers, the smart move is clear: keep investing in classical AI, simulations, and supercomputers, while also preparing for quantum by nurturing talent, forming strategic partnerships, and staying ahead of cybersecurity threats. But here’s the twist: many experts warn about a looming “quantum divide,” where only a select few governments, big research labs, and tech giants have access to these powerful quantum tools. That raises a big question:

Will the future be a fair and inclusive landscape where everyone benefits from quantum advances, or will it become a high-stakes game where a small elite pulls further ahead, leaving other countries behind?

Learn Hybrid Quantum Computing in 25 Minutes

References

IBM (2025) The dawn of quantum advantage. IBM Quantum Computing Blog, 21 July 2025 (updated 5 May 2026). Available at: https://www.ibm.com/quantum/blog/quantum-advantage-era (Accessed: 16 June 2026).

IBM (2026a) Quantum 2026 — IBM Technology Atlas. Available at: https://www.ibm.com/roadmaps/quantum/2026/ (Accessed: 15 July 2026).

IBM (2026b) What is quantum-centric supercomputing? Available at: https://www.ibm.com/think/topics/quantum-centric-supercomputing (Accessed: 16 July 2026).

IBM Newsroom (2026) IBM Releases a New Blueprint for Quantum-Centric Supercomputing, 12 March 2026. Available at: https://newsroom.ibm.com/2026-03-12-ibm-releases-a-new-blueprint-for-quantum-centric-supercomputing  (Accessed: 16 July 2026).

IBM Research (2026) Unveiling the first reference architecture for quantum-centric supercomputing, 12 March 2026. Available at: https://research.ibm.com/blog/quantum-centric-supercomputing-system-reference-architecture (Accessed: 1 June 2026).

IntuitionLabs (2026) IBM Quantum’s Role in Pharmaceutical Drug Discovery (revised 8 March 2026). Available at: https://intuitionlabs.ai/articles/ibm-quantum-drug-discovery (Accessed: 10 July 2026).

Nature Biotechnology (2026) ‘Quantum computing in transition’, Nature Biotechnology, 44, pp. 1065–1066, 6 July 2026. doi:10.1038/s41587-026-03233-x. Available at: https://www.nature.com/articles/s41587-026-03233-x (Accessed: 16 July 2026).

Sama, A. (2025) Towards Quantum Advantage and Useful Quantum, 2026 and Beyond. Medium, 28 October 2025. Available at: https://andisama.medium.com/towards-quantum-advantage-and-useful-quantum-2026-and-beyond-c0f688520b08 (Accessed: 16 July 2026).

The Quantum Insider (2026a) Quantum Machine Learning Is Emerging as a Practical Tool for Drug Discovery, 21 January 2026. Available at: https://thequantuminsider.com/2026/01/21/quantum-machine-learning-is-emerging-as-a-practical-tool-for-drug-discovery/ (Accessed: 16 July 2026).

The Quantum Insider (2026b) IBM’s Krishna Predicts First Real-World Quantum Advantage in 2026, 30 April 2026. Available at: https://thequantuminsider.com/2026/04/30/ibms-krishna-predicts-first-real-world-quantum-advantage-in-2026/ (Accessed: 16 July 2026).

Zhou, Y., Chen, J., Cheng, J. et al. (2026) ‘Quantum-machine-assisted drug discovery’, npj Drug Discovery, 3(1), 7 January 2026. Available at: https://www.nature.com/articles/s44386-025-00033-2 (Accessed: 16 July 2026).